Analysts’ ratings for Mednax
Of the total 14 analysts covering Mednax (MD) in December 2017, three analysts have given the stock a “buy” or higher rating and ten have given it a “hold” rating while one analyst has given it a “sell” rating. The mean rating for the stock is 2.71 with a mean target price of $48.18.
Notably, Mednax makes up about 0.26% of the iShares Core S&P Mid-Cap ETF’s (IJH) total portfolio holdings.
Of the 20 analysts covering Lifepoint Health (LPNT) in December 2017, five analysts have given the stock a “buy” or higher rating and two analysts have given it a “sell” or lower rating. For Acadia Healthcare Company (ACHC), of the 17 analysts covering the company, ten have given the stock a “buy” or higher rating. Meanwhile, of the 15 analysts covering Envision Healthcare (EVHC), 11 have given it a “buy” or higher rating and five analysts have given it a “hold” rating.
In the next part of this series, we take a look at Mednax’s business strategy.